Bryant and colleagues follow the development of Glybera (alipogene tiparvovec), the first gene therapy product approved in the European Union, from early preclinical studies through the approval process. They review key data from human and animal studies with an emphasis on issues that will be critical to other gene therapy products. The article concludes with an analysis of the complex review process that eventually led to Glybera's approval.
Get full access to this article
View all access options for this article.
References
1.
AsokanA., SchafferD.V., SamulskiR.J.2012. The AAV vector toolkit: Poised at the clinical crossroads. Mol. Ther., 20:699–708.
GaudetD., De WalJ., TremblayK.et al.2010. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler. Suppl., 11:55–60.
8.
GaudetD., MethotJ., DeryS.et al.2013. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: An open-label trial. Gene Ther., 20:361–369.
9.
GotodaT., SendaM., GamouT.et al.1989. Nucleotide sequence of human cDNA coding for a lipoprotein lipase (LPL) cloned from placental cDNA library. Nucleic Acids Res., 17:2351.
10.
KasteleinJ.J., RossC.J., HaydenM.R.2013. From mutation identification to therapy: Discovery and origins of the first approved gene therapy in the Western world. Hum. Gene Ther., 24:472–478.
11.
MannoC.S., PierceG.F., ArrudaV.R.et al.2006. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med., 12:342–347.
12.
MeadJ.R., IrvineS.A., RamjiD.P.2002. Lipoprotein lipase: Structure, function, regulation, and role in disease. J. Mol. Med. (Berl.), 80:753–769.
13.
MingozziF., LiuY.L., DobrzynskiE.et al.2003. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Invest., 111:1347–1356.
14.
National Institutes of Health (NIH). 2009. Efficacy and safety of human lipoprotein lipase (LPL)[S447X] expressed by an adeno-associated viral vector in LPL-deficient subjects. http://www.clinicaltrials.gov/ct2/show/NCT00891306.
15.
National Institutes of Health (NIH). 2010. Safety and efficacy in LPL-deficient subjects of AMT-011, an adeno-associated viral vector expressing human lipoprotein lipase [S447X]http://www.clinicaltrials.gov/ct2/show/NCT01109498.
16.
RipJ., NiermanM.C., SiertsJ.A.et al.2005. Gene therapy for lipoprotein lipase deficiency: Working toward clinical application. Hum. Gene Ther., 16:1276–1286.
17.
RossC.J., TwiskJ., MeulenbergJ.M.et al.2004. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPLS447X beneficial mutation. Hum. Gene Ther., 15:906–919.
18.
RossC.J., LiuG., KuivenhovenJ.A.et al.2005. Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation. Arterioscler. Thromb. Vasc. Biol., 25:2143–2150.
19.
RossC.J., TwiskJ., BakkerA.C.et al.2006. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum. Gene Ther., 17:487–499.
